A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
The purpose of this study is to evaluate the safety and efficacy of abciximab, an anti-platelet therapy, versus placebo in patients with unstable angina who are not responding to standard medical therapy and who are eligible for coronary angioplasty.
Angioplasty, Transluminal, Percutaneous Coronary
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Chimeric Anti-Platelet Therapy (Abciximab) in Unstable Angina Refractory to Standard Medical Therapy Trial (CAPTURE)|
- Any of the following within 30 days: Death from any cause
- Myocardial infarction; or Recurrent ischemic events requiring urgent intervention (coronary artery bypass surgery, repeat coronary angioplasty, coronary stent placement, intra-aortic balloon pump)
- Components of the primary endpoint: Recurrent ischemia before or after the planned angioplasty; Myocardial infarction; Repeat angioplasty; Coronary artery bypass surgery; Deaths
This is a randomized, placebo-controlled study to evaluate the safety and efficacy of abciximab, an anti-platelet therapy, in patients with unstable angina who are not responding to standard medical therapy and who are eligible for coronary angioplasty. The primary outcomes of the study include any of the following within 30 days: the number of deaths from any cause, myocardial infarctions or the number of recurrent ischemic events requiring urgent intervention (such as a coronary artery bypass surgery, repeat coronary angioplasty, coronary stent placement, or intra-aortic balloon pump). Please see attached results.
Patients will be treated with abciximab or matching placebo.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00269906
|Study Director:||Centocor, Inc. Clinical Trial||Centocor, Inc.|